|
|
Article: FDA Approves Labeling Showing Xenical(R) (orlistat) Treatment Resulted in 42% Reduction in Relative Risk of Developing Type 2 Diabetes; XENDOS Study Demonstrates that Treatment With Xenical Resulted in More Weight Loss and Significant Delay in Onset of Type 2 Diabetes in Obese Patients With Impaired Glucose Tolerance Compared to Diet Alone.
- Article from:
- PR Newswire
- Article date:
- October 29, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
NUTLEY, N.J., Oct. 29 /PRNewswire/ -- Roche today announced that the U.S. Food and Drug Administration (FDA) has approved labeling showing that weight loss with Xenical(R) (orlistat) delayed the onset of type 2 diabetes in obese patients with impaired glucose tolerance (IGT or pre-diabetes).
The label change is based on results from the XENDOS (Xenical in the Prevention of Diabetes in Obese Subjects) study, the largest and longest study to date of a weight loss medication. XENDOS assessed the delay in onset of diabetes and weight loss in 3304 obese patients (BMI greater than or equal to 30) with either normal (n=2643) or impaired glucose tolerance (n=661) in a ...